FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943914303> ?p ?o ?g. }

• W2943914303 abstract "Background: The use of neoadjuvant platinum with taxane for triple negative breast cancer (TNBC) has gained increased attention for improving rates of pathologic complete response (pCR). Our prior trial combining carboplatin (CAR) with liposomal doxorubicin (DOX) for metastatic TNBC showed good response rates with minimal side effects while allowing for greater platinum dosing compared to a taxane combination. We hypothesized that the doublet of DOX+CAR is effective and tolerable in the neoadjuvant setting for TNBC and that tumor genomics may aid in determining those patients most likely to benefit. Methods: A phase II single arm trial was conducted for patients (pts) diagnosed with stage II-III TNBC. Patients received 4 cycles of neoadjuvant carboplatin (AUC 5) and liposomal doxorubicin (30mg/m2) administered every 28 days, then underwent definitive breast surgery followed by 12 weeks of adjuvant paclitaxel 80 mg/m2 administered weekly. Primary and secondary clinical endpoints were rate of pCR and two year recurrence free survival (RFS) and overall survival (OS), respectively. Cardiac safety of the combination was assessed. Fresh residual tumor samples were obtained at time of surgery for generation of patient derived xenografts (PDX). Tumor genomic profiling was done to determine the mutational spectrum, association of this spectrum in primary tumors with achieving pCR, and identifying alternative treatment strategies for PDX evaluation for patients with resistant disease. Results: From 2/2015 to 5/2018, 36 pts were enrolled and 32 completed treatment; 4 pts await definitive surgery; 12 (33%) are two years from diagnosis. Median age of the cohort was 53 years. There was high participation by under-represented groups: 23% African American, 20% Asian, 14% Hispanic. Most histologies were invasive ductal but included apocrine, pleomorphic lobular, and metaplastic subtypes. Of the 32 pts who completed surgery, 34% (11) achieved pCR and 64% (23) had clinical response on serial physical exam. At 2 years, there were 2 distant and 1 local recurrence. The most common toxicities during DOX+CAR were grade 1 nausea in 19 pts (53%), grade 3/4 neutropenia occurred in 10 pts (28%); these pts received GCSF support with subsequent cycles; febrile neutropenia occurred in 1 pt (3%) in this group. Grade 3 thrombocytopenia (2 pts), pruritis (1 pt), and mucositis (1 pt) were observed. Only 6 pts (17%) had grade 1 alopecia. There were no delays in treatment due to cardiotoxicity or complications from surgical healing. TP53 (93%), PI3K/PTEN (26.6%), and NOTCH (20%) were the most commonly altered pathways. Structural variants, such as amplifications, rearrangements, and frameshifts were the most frequent alterations detected. Of the 25 pts who had residual disease, PDX was attempted from 14 pts, and 10 (71%) PDX were established, including those for all 3 patients experiencing recurrence. Conclusion: Neoadjuvant DOX+CAR demonstrated good efficacy and tolerability. Post-chemotherapy PDX is feasible and may help identify targeted approaches for patients with resistant disease. These results warrant further evaluation of this combination for early stage TNBC. Citation Format: Chan N, Riedlinger GM, Lu S-e, Pham KT, Kirstein LJ, Eladoumikdachi FG, George MA, Potdevin LB, Kowzun MJ, Desai SA, Tang DM, Omene CO, Wong ST, Rodriguez-Rust L, Kumar S, Kearney TJ, Liu C, Ganesan S, Toppmeyer DL, Hirshfield KM. Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-15-14." @default.
• W2943914303 created "2019-05-16" @default.
• W2943914303 creator A5000783323 @default.
• W2943914303 creator A5000830816 @default.
• W2943914303 creator A5003689223 @default.
• W2943914303 creator A5003963283 @default.
• W2943914303 creator A5010801087 @default.
• W2943914303 creator A5010867903 @default.
• W2943914303 creator A5011502372 @default.
• W2943914303 creator A5013082158 @default.
• W2943914303 creator A5014469413 @default.
• W2943914303 creator A5027370711 @default.
• W2943914303 creator A5061989008 @default.
• W2943914303 creator A5076698616 @default.
• W2943914303 creator A5080150420 @default.
• W2943914303 creator A5081735541 @default.
• W2943914303 creator A5083705513 @default.
• W2943914303 creator A5084664916 @default.
• W2943914303 creator A5084839704 @default.
• W2943914303 creator A5087162958 @default.
• W2943914303 creator A5088353423 @default.
• W2943914303 creator A5089019234 @default.
• W2943914303 date "2019-02-15" @default.
• W2943914303 modified "2023-09-27" @default.
• W2943914303 title "Abstract P1-15-14: Neoadjuvant liposomal doxorubicin and carboplatin is effective and tolerable for the treatment of triple negative breast cancer" @default.
• W2943914303 doi "https://doi.org/10.1158/1538-7445.sabcs18-p1-15-14" @default.
• W2943914303 hasPublicationYear "2019" @default.
• W2943914303 type Work @default.
• W2943914303 sameAs 2943914303 @default.
• W2943914303 citedByCount "0" @default.
• W2943914303 crossrefType "proceedings-article" @default.
• W2943914303 hasAuthorship W2943914303A5000783323 @default.
• W2943914303 hasAuthorship W2943914303A5000830816 @default.
• W2943914303 hasAuthorship W2943914303A5003689223 @default.
• W2943914303 hasAuthorship W2943914303A5003963283 @default.
• W2943914303 hasAuthorship W2943914303A5010801087 @default.
• W2943914303 hasAuthorship W2943914303A5010867903 @default.
• W2943914303 hasAuthorship W2943914303A5011502372 @default.
• W2943914303 hasAuthorship W2943914303A5013082158 @default.
• W2943914303 hasAuthorship W2943914303A5014469413 @default.
• W2943914303 hasAuthorship W2943914303A5027370711 @default.
• W2943914303 hasAuthorship W2943914303A5061989008 @default.
• W2943914303 hasAuthorship W2943914303A5076698616 @default.
• W2943914303 hasAuthorship W2943914303A5080150420 @default.
• W2943914303 hasAuthorship W2943914303A5081735541 @default.
• W2943914303 hasAuthorship W2943914303A5083705513 @default.
• W2943914303 hasAuthorship W2943914303A5084664916 @default.
• W2943914303 hasAuthorship W2943914303A5084839704 @default.
• W2943914303 hasAuthorship W2943914303A5087162958 @default.
• W2943914303 hasAuthorship W2943914303A5088353423 @default.
• W2943914303 hasAuthorship W2943914303A5089019234 @default.
• W2943914303 hasConcept C121608353 @default.
• W2943914303 hasConcept C126322002 @default.
• W2943914303 hasConcept C141071460 @default.
• W2943914303 hasConcept C143998085 @default.
• W2943914303 hasConcept C203092338 @default.
• W2943914303 hasConcept C2776694085 @default.
• W2943914303 hasConcept C2777511904 @default.
• W2943914303 hasConcept C2778239845 @default.
• W2943914303 hasConcept C2778292576 @default.
• W2943914303 hasConcept C2780110267 @default.
• W2943914303 hasConcept C2780258809 @default.
• W2943914303 hasConcept C2781303535 @default.
• W2943914303 hasConcept C2781451048 @default.
• W2943914303 hasConcept C530470458 @default.
• W2943914303 hasConcept C535046627 @default.
• W2943914303 hasConcept C71924100 @default.
• W2943914303 hasConceptScore W2943914303C121608353 @default.
• W2943914303 hasConceptScore W2943914303C126322002 @default.
• W2943914303 hasConceptScore W2943914303C141071460 @default.
• W2943914303 hasConceptScore W2943914303C143998085 @default.
• W2943914303 hasConceptScore W2943914303C203092338 @default.
• W2943914303 hasConceptScore W2943914303C2776694085 @default.
• W2943914303 hasConceptScore W2943914303C2777511904 @default.
• W2943914303 hasConceptScore W2943914303C2778239845 @default.
• W2943914303 hasConceptScore W2943914303C2778292576 @default.
• W2943914303 hasConceptScore W2943914303C2780110267 @default.
• W2943914303 hasConceptScore W2943914303C2780258809 @default.
• W2943914303 hasConceptScore W2943914303C2781303535 @default.
• W2943914303 hasConceptScore W2943914303C2781451048 @default.
• W2943914303 hasConceptScore W2943914303C530470458 @default.
• W2943914303 hasConceptScore W2943914303C535046627 @default.
• W2943914303 hasConceptScore W2943914303C71924100 @default.
• W2943914303 hasLocation W29439143031 @default.
• W2943914303 hasOpenAccess W2943914303 @default.
• W2943914303 hasPrimaryLocation W29439143031 @default.
• W2943914303 hasRelatedWork W2227329646 @default.
• W2943914303 hasRelatedWork W2331329572 @default.
• W2943914303 hasRelatedWork W2479591986 @default.
• W2943914303 hasRelatedWork W2593159593 @default.
• W2943914303 hasRelatedWork W2679105044 @default.
• W2943914303 hasRelatedWork W2810698795 @default.
• W2943914303 hasRelatedWork W2943914303 @default.
• W2943914303 hasRelatedWork W2946370795 @default.
• W2943914303 hasRelatedWork W3045640397 @default.
• W2943914303 hasRelatedWork W3095199482 @default.
• W2943914303 isParatext "false" @default.
• W2943914303 isRetracted "false" @default.
• W2943914303 magId "2943914303" @default.
• W2943914303 workType "article" @default.